JS014 not checked

Anwita Biosciences

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Weekly infusion at the designated dose level until disease progression, withdrawal or up to two years”In the company’s words, NCT05296772 on ClinicalTrials.gov
Tested for
Neoplasm Malignant, Neoplasm, Experimental, Solid Tumor, Adult, Lymphoma
Main trialPhase 1
“This phase 1, first-in-human study uses a BOIN design to assess the safety and potential efficacy of JS014 at different dose levels as a single agent and in combination with fixed dose of pembrolizumab in subjects with advanced cancer.”In the company’s words, NCT05296772 on ClinicalTrials.gov

Other drugs for Neoplasm Malignant

All 2440 drugs for Neoplasm Malignant

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Unknown Jun 2024 Phase 1 First-in-human Study of JS014
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JS014

Following is part of Solo: you see every change to JS014 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in